ISOX DUAL

Discontinued Product

5806 has been discontinued.

View all Bromodomains products.
Description: Dual BRD4 and CBP/p300 bromodomain inhibitor
Chemical Name: [3-[4-[2-[5-(Dimethyl-1,2-oxazol-4-yl)-1-[2-(morpholin-4-yl)ethyl]-1H-1,3-benzodiazol-2-yl]ethyl]phenoxy]propyl]dimethylamine
Purity: ≥98% (HPLC)
Datasheet
Citations
Reviews
Literature (4)

Biological Activity for ISOX DUAL

ISOX DUAL is a dual CBP/p300 and BRD4 bromodomain inhibitor (IC50 values are 0.65 and 1.5 μM for CBP and BRD4 respectively). Downregulates IL-6, IL-1β and IFN-β in macrophages.

Licensing Information

Sold for research purposes under agreement from Pfizer Inc.

Technical Data for ISOX DUAL

M. Wt 531.69
Formula C31H41N5O3
Storage Store at +4°C
Purity ≥98% (HPLC)
CAS Number 1962928-22-8
PubChem ID 121237857
InChI Key HCDQWCDANVEBQR-UHFFFAOYSA-N
Smiles CC(ON=C1C)=C1C2=CC(N=C(CCC3=CC=C(OCCCN(C)C)C=C3)N4CCN5CCOCC5)=C4C=C2

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Product Datasheets for ISOX DUAL

Certificate of Analysis / Product Datasheet
Select another batch:

References for ISOX DUAL

References are publications that support the biological activity of the product.

Chekler (2015) Transcriptional profiling of a selective CREB binding protein bromodomain inhibitor highlights therapeutic opportunities. Chem.Biol. 22 1588 PMID: 26670081

View Related Products by Product Action

View all Bromodomain Inhibitors

Keywords: ISOX DUAL, ISOX DUAL supplier, Dual, CBP/p300, BRD4, bromodomains, inhibitors, inflammation, macrophages, inhibits, Bromodomains, Histone, Acetyltransferases, 5806, Tocris Bioscience

Citations for ISOX DUAL

Citations are publications that use Tocris products.

Currently there are no citations for ISOX DUAL.

Reviews for ISOX DUAL

There are currently no reviews for this product. Be the first to review ISOX DUAL and earn rewards!

Have you used ISOX DUAL?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Stem Cell Research Product Guide

Stem Cell Research Product Guide

This product guide provides a background to the use of small molecules in stem cell research and lists over 200 products for use in:

  • Self-renewal and Maintenance
  • Differentiation
  • Reprogramming
  • Organoid Generation
  • GMP and Ancillary Material Grade Products
Epigenetics Scientific Review

Epigenetics Scientific Review

Written by Susanne Müller-Knapp and Peter J. Brown, this review gives an overview of the development of chemical probes for epigenetic targets, as well as the impact of these tool compounds being made available to the scientific community. In addition, their biological effects are also discussed. Epigenetic compounds available from Tocris are listed.

Epigenetics in Cancer Poster

Epigenetics in Cancer Poster

This poster summarizes the main epigenetic targets in cancer. The dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible and thus make promising therapeutic targets.

Rheumatoid Arthritis Poster

Rheumatoid Arthritis Poster

Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.